Researchers at Pisa's Scuola Superiore Sant'Anna and King's College London have shown that therapeutic administration of miR-199 stimulated cardiac repair in pigs after experimentally induced heart attacks.
PHILADELPHIA – "Because of our assumption that structure determines function, for a long time [low-complexity domains] were not considered important," J. Paul Taylor told the audience at the American Academy of Neurology (AAN) annual meeting's Frontiers in Neuroscience plenary session. Such low-complexity domains (LCDs) were thought of as junk parts of proteins, in analogy to junk DNA.
PHILADELPHIA – "We've gone from no randomized controlled trial to three," Sean Pittock told reporters at the American Academy of Neurology (AAN) annual meeting this week. "It's a glorious example of what you can do with precision medicine."
Researchers have discovered that the synaptic protein Bassoon accumulated in the neurons of mice with experimental autoimmune encephalitis, the closest animal model to multiple sclerosis (MS), causing neuronal damage in much the same way that protein aggregates damage neurons in neurodegenerative diseases.
PHILADELPHIA – Data presented at the American Academy of Neurology (AAN) meeting this week on experimental therapeutics for Huntington's disease gave some cause for optimism. And, as good research does, they identified new questions as they answered current ones.
Researchers have linked the hormone oxytocin, which stimulates social and pair bonding, to the increased risk of aortic tear in women with Marfan syndrome.
"The molecular genetics for APP" – amyloid precursor protein – "still unequivocally demonstrate that APP and Abeta are crucial for disease pathogenesis" in Alzheimer's disease (AD), Carlo Condello told BioWorld.
Researchers have discovered that the synaptic protein Bassoon accumulated in the neurons of mice with experimental autoimmune encephalitis, the closest animal model to multiple sclerosis (MS), causing neuronal damage in much the same way that protein aggregates damage neurons in neurodegenerative diseases.
Three phase I trials – I-PREDICT, TARGET and WINTHER – published back to back in the April 22, 2019, issue of Nature Medicine have reported progress on a central goal of precision medicine: the rapid delivery of therapy tailored to the molecular details of a patient's illness.
